Bupropion-Dextromethorphan Combination for CYP2D6 Metabolism Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for depression, particularly in extensive metabolizers of dextromethorphan, are limited by low plasma levels of dextromethorphan due to rapid metabolism, and treatment-resistant depression poses challenges with inadequate responses to multiple antidepressants, including increased risk of suicide.

Innovation Solution

Administering a combination of bupropion and dextromethorphan, with bupropion inhibiting dextromethorphan metabolism to increase plasma levels, allowing for less frequent dosing while improving therapeutic efficacy, particularly in extensive metabolizers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If dextromethorphan is administered alone, then it provides antidepressant effect, but plasma levels are low due to rapid metabolism in extensive metabolizers

Engineering Contradiction:
Improveplasma level of dextromethorphanVSAvoidtherapeutic efficacy
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

Bupropion acts as a metabolic inhibitor that mediates between dextromethorphan administration and its metabolism by CYP2D6 enzyme. By introducing this intermediary substance, the patent achieves sustained plasma levels of dextromethorphan in extensive metabolizers, resolving the contradiction between rapid metabolism and therapeutic efficacy.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the metabolic parameter of dextromethorphan by co-administering bupropion, which alters the metabolism rate. This parameter change transforms dextromethorphan from a rapidly metabolized substance with low plasma levels to one with sustained plasma levels and improved therapeutic efficacy in extensive metabolizers.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If multiple antidepressants are tried for treatment-resistant depression, then various treatments are attempted, but response remains inadequate and suicide risk increases

Engineering Contradiction:
Improveresponse to treatmentVSAvoidsuicide risk
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines two substances with different mechanisms of action (dextromethorphan as NMDA receptor antagonist and bupropion as NDRI) into a composite treatment regimen. This composite approach provides synergistic antidepressant effects and reduces suicide risk more effectively than single agents, addressing treatment-resistant depression.

Inventive Principle:
Principle #40Composite materials

3Reliability

If dextromethorphan is dosed frequently to maintain plasma levels, then therapeutic effect improves, but dosing complexity increases

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoiddosing frequency
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

Bupropion serves as a mediator that extends the half-life of dextromethorphan by inhibiting its metabolism. This allows dextromethorphan to be administered less frequently (e.g., once or twice daily instead of multiple times), reducing dosing complexity while maintaining therapeutic efficacy.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination significantly reduces MADRS scores, improving depression symptoms and reducing suicidal ideation, with MADRS score reductions up to 82.4% in patients with suicidal ideation within four weeks.

Implementation Method 1

Dextromethorphan is rapidly metabolized in the human liver by the CYP2D6 enzyme. This rapid hepatic metabolism may limit systemic drug exposure in individuals who are extensive metabolizers.

Methodology Applied
Scientific EffectCYP2D6 enzyme metabolism: Enzyme

Implementation Method 2

Bupropion inhibits the metabolism of dextromethorphan, and raises the plasma concentration of dextromethorphan

Methodology Applied
Scientific EffectMetabolic inhibition: Enzyme

Data Source

PatentUS20260041651A1Bupropion and dextromethorphan for reduction of suicide risk in depression patients
Publication Date: 2026.02.12 ANTECIP BIOVENTURES II LLC

AI summary

This disclosure relates to a method of treating depression and/or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).